IRIS
TOSCANI, Denise
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.074
AS - Asia 3.135
EU - Europa 2.121
SA - Sud America 446
AF - Africa 225
Continente sconosciuto - Info sul continente non disponibili 158
OC - Oceania 2
Totale 10.161
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.912
SG - Singapore 1.011
CN - Cina 862
IT - Italia 515
VN - Vietnam 506
SE - Svezia 377
BR - Brasile 326
IE - Irlanda 312
HK - Hong Kong 215
DE - Germania 184
FI - Finlandia 170
BD - Bangladesh 163
ZA - Sudafrica 148
FR - Francia 139
TR - Turchia 114
CA - Canada 90
NL - Olanda 84
AT - Austria 67
IN - India 66
GB - Regno Unito 58
RU - Federazione Russa 52
AR - Argentina 43
MX - Messico 33
BE - Belgio 26
CZ - Repubblica Ceca 25
CI - Costa d'Avorio 24
JP - Giappone 24
IQ - Iraq 21
CO - Colombia 20
ES - Italia 19
KR - Corea 19
RO - Romania 19
PL - Polonia 18
VE - Venezuela 16
PK - Pakistan 15
UA - Ucraina 15
EC - Ecuador 14
ID - Indonesia 14
TH - Thailandia 14
PH - Filippine 13
CL - Cile 9
UZ - Uzbekistan 9
AE - Emirati Arabi Uniti 8
KE - Kenya 8
LT - Lituania 8
TN - Tunisia 8
CR - Costa Rica 7
MA - Marocco 7
PY - Paraguay 7
EG - Egitto 6
EU - Europa 6
IL - Israele 6
KZ - Kazakistan 6
TW - Taiwan 6
AL - Albania 5
JM - Giamaica 5
SA - Arabia Saudita 5
BG - Bulgaria 4
BO - Bolivia 4
IR - Iran 4
KW - Kuwait 4
MY - Malesia 4
PE - Perù 4
RS - Serbia 4
SN - Senegal 4
TT - Trinidad e Tobago 4
AZ - Azerbaigian 3
BW - Botswana 3
CW - ???statistics.table.value.countryCode.CW??? 3
DZ - Algeria 3
EE - Estonia 3
ET - Etiopia 3
GT - Guatemala 3
JO - Giordania 3
NI - Nicaragua 3
OM - Oman 3
SC - Seychelles 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
UY - Uruguay 3
AM - Armenia 2
BY - Bielorussia 2
BZ - Belize 2
CH - Svizzera 2
DK - Danimarca 2
HN - Honduras 2
HU - Ungheria 2
MD - Moldavia 2
MU - Mauritius 2
NO - Norvegia 2
NP - Nepal 2
PR - Porto Rico 2
PT - Portogallo 2
QA - Qatar 2
XK - ???statistics.table.value.countryCode.XK??? 2
AG - Antigua e Barbuda 1
AU - Australia 1
BB - Barbados 1
BH - Bahrain 1
BJ - Benin 1
Totale 9.992
Salva come PNG Salva come JPEG
Città #
Ashburn 553
Singapore 491
San Jose 438
Chandler 310
Dublin 309
Santa Clara 285
Dallas 253
Beijing 220
Hong Kong 206
Parma 180
Ho Chi Minh City 162
Council Bluffs 144
Johannesburg 141
Hanoi 118
Boardman 111
New York 111
Ann Arbor 108
Los Angeles 106
Shanghai 91
Izmir 90
Dearborn 75
Munich 71
Lauterbourg 68
Nanjing 64
Vienna 62
Princeton 57
Buffalo 48
Hefei 39
Milan 38
Shenyang 38
Marseille 35
São Paulo 32
Toronto 32
Helsinki 29
Bologna 28
Jacksonville 28
Wilmington 27
Brussels 26
Columbus 26
Düsseldorf 25
Abidjan 24
Da Nang 24
Kunming 24
Moscow 24
Hebei 23
Haiphong 20
Montreal 20
Nanchang 20
Turku 20
Atlanta 19
Tokyo 19
Jinan 18
Rome 18
Seattle 18
Chicago 17
North Bergen 17
San Mateo 17
Brno 16
Jiaxing 16
Orem 16
The Dalles 16
Tianjin 16
Phoenix 15
Warsaw 15
Bremen 14
London 14
Brooklyn 13
Norwalk 13
Frankfurt am Main 12
Houston 12
San Francisco 12
Seoul 12
Stockholm 12
Denver 11
Washington 11
Biên Hòa 10
Kocaeli 10
Modena 10
Redmond 10
Woodbridge 10
Changsha 9
Chennai 9
Focsani 9
Jakarta 9
Philadelphia 9
Ankara 8
Belo Horizonte 8
Des Moines 8
Mexico City 8
Poplar 8
Tashkent 8
Zhengzhou 8
Amsterdam 7
Baghdad 7
Can Tho 7
Guangzhou 7
Hải Dương 7
Naples 7
Newark 7
Ottawa 7
Totale 6.070
Salva come PNG Salva come JPEG
Nome #
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 236
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 229
(2S,4R)-4-fluoroglutamine is converted into (2S,4R)-4-fluoroglutamate by glutaminase activity and may be exploited as a PET tracer in glutamine-addicted cancers 218
[18F](2S,4R)-4-Fluoroglutamine as a New Positron Emission Tomography Tracer in Myeloma 218
Follow-up of humoral and cellular immune responses after the third SARS-CoV-2 vaccine dose in multiple myeloma patients 210
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 206
Novel targets for the treatment of relapsing multiple myeloma 205
Role of 1q21 in multiple myeloma: From pathogenesis to possible therapeutic targets 205
Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma 200
The Proteasome and Myeloma-Associated Bone Disease 200
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 197
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 196
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 192
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 188
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 187
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 186
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 186
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 182
A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors 181
ADENOSINE IN THE MYELOMA BONE MARROW NICHE: IMMUNE CHECKPOINT AND KEY PLAYER IN DISEASE PROGRESSION 176
Bortezomib improves bone integrity in multiple myeloma patients by blocking osteocyte death and autophagy 169
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 166
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 165
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 162
Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells 160
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 156
Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma. 155
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 155
High glutamate levels in the bone marrow of multiple myeloma patients promote osteoclast formation: a novel target for osteolytic bone disease 154
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies 154
The impact of CD56 expression in smoldering myeloma patients on early progression 150
The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38 149
The osteoblastic niche in the context of multiple myeloma 147
Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2 145
Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells 145
Mechanistic insights into bone destruction in multiple myeloma: Cellular and molecular perspectives 142
Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis 141
Possible targets to treat myeloma-related osteoclastogenesis 138
CK2 Kinase Inhibitors Display Anti-Myeloma Effects and Antagonize Osteoclast Activity in Models of Multiple Myeloma Bone Marrow Microenvironment 137
Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis 136
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response 131
Hypoxia-inducible factor (HIF)-1 is a therapeutic target in myeloma-induced angiogenesis and bone destruction in vitro and in vivo 130
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 128
Gfi1 Transcription Factor Is a Pro-Survival Molecule in Multiple Myeloma Cells 128
Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma 126
Trascriptome Analysis of Bone Marrow CD14+ Monocytes Revealed Differential Expression Profiles in Symptomatic Multiple Myeloma (MM) Compared to Smoldering MM and Monoclonal Gammopathy of Undetermined Significance 120
Proteasome Inhibitors Block Myeloma-Induced Osteocyte Death in Vitro and in Vivo in Multiple Myeloma Patients 118
The Metabolic Features of Osteoblasts: Implications for Multiple Myeloma (MM) Bone Disease 116
Relationship between bone imaging features and bone marrow cytokine and chemokine profiles in patients with monoclonal gammopathy 116
Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction 116
NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model 114
Hypoxia-Inducible Factor (HIF)-1a Is A Therapeutic Target in Myeloma-Induced Angiogenesis and Bone Destruction in Vivo 112
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 110
The role of proteasome inhibitors in multiple myeloma bone disease and bone metastasis: Effects on osteoblasts and osteocytes 110
Pygo2 Is Overexpressed in Myeloma Cells With 1q21 Amplification Being Involved in Carfilzomib Resistance 108
Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease 108
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors 106
The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma 101
Interleukin-3 induces activin A in bone marrow monocytes: role in multiple myeloma patients 99
Proteasome inhibitors modulate osteocyte death and autophagy in multiple myeloma 98
Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+ 95
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules 93
New insights into osteogenic and chondrogenic differentiation of human bone marrow mesenchymal stem cells and their potential clinical applications for bone regeneration in pediatric orthopaedics 91
Myeloma-Induced osteocyte death was blunted by proteasome inhibitors through the modulation of autophagy 91
Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: Impact on myeloma-induced alterations of bone remodeling 90
Role of osteocytes in myeloma bone disease: Anti-sclerostin antibody as new therapeutic strategy 78
A metabolic trade-off between malignant plasma cells and mesenchymal stromal cells sustains multiple myeloma growth 62
FROM PRECURSOR DISEASES TO MULTIPLE MYELOMA: REMODELING OF THE OSTEOBLASTIC NICHE AT SINGLE CELL RESOLUTION 57
PYGO2 is overexpressed in multiple myeloma patients with 1q21 amplification, driving plasma cell proliferation and cell cycle progression 51
TARGETING GLUTAMINE METABOLISM POTENTIATES T CELL ENGAGER–MEDIATED IMMUNOTHERAPY IN MULTIPLE MYELOMA 41
Oncolytic bovine herpesvirus type 1 induces immune microenvironment remodeling and enhances treatment responses in multiple myeloma 37
Long-term prognostic impact of chromosome 1 abnormalities in newly diagnosed multiple myeloma patients: a monocentric study 29
Proteasome inhibitors blunt myeloma induced osteocyte death targeting autophagy both in vitro and in vivo in multiple myeloma patients 27
Totale 10.161
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.388
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.388
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022237 0 0 0 0 9 6 41 32 13 16 23 97
2022/20231.282 144 139 92 99 101 140 41 80 372 30 31 13
2023/2024556 26 37 12 14 36 185 51 22 14 35 27 97
2024/20251.663 34 75 89 154 176 171 107 75 197 128 158 299
2025/20264.084 328 307 521 379 531 217 375 178 473 384 251 140
2026/2027946 119 207 254 356 10 0 0 0 0 0 0 0
Totale 10.161